HC Wainwright began coverage on shares of Ovid Therapeutics (NASDAQ:OVID – Free Report) in a research note issued to investors on Monday morning, Marketbeat.com reports. The firm issued a buy rating and a $9.00 price objective on the stock. HC Wainwright also issued estimates for Ovid Therapeutics’ Q1 2024 earnings at ($0.22) EPS, Q2 2024 […]
Related Keywords
United States , Jeremym Levin , , Wealth Management , Sg Americas Securities , Ovid Therapeutics Inc , Nasdaq , Securities Exchange Commission , Connor Clark Lunn Investment Management Ltd , Ovid Therapeutics , Free Report , Get Free Report , Exchange Commission , Point Capital , Lunn Investment Management , Therapeutics Inc , Ovid Therapeutics Daily , Nasdaq Ovid , Covid , Medical , Initiated Coverage , Hc Wainwright ,
vimarsana.com © 2020. All Rights Reserved.